FDA.reportPublic FDA data

kygevvi 2 GM / 2 GM Powder for Oral Solution

RxCUI
2737541
RxNorm name
kygevvi 2 GM / 2 GM Powder for Oral Solution
Display name
kygevvi 2 GM / 2 GM Powder for Oral Solution
Full name
kygevvi 2 GM / 2 GM Powder for Oral Solution
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:39:05

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
KYGEVVIDOXECITINE AND DOXRIBTIMINEUCB, Inc.7d5ce670-9314-4fd7-8b0a-1447910dcf9e2025-11-10Warnings, Adverse reactionsExact identifier
rxcui: 2737541

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
7d5ce670-9314-4fd7-8b0a-1447910dcf9ekygevvi 2 GM / 2 GM Powder for Oral SolutionPSN3These highlights do not include all the information needed to use KYGEVVI safely and effectively. See full prescribing information for KYGEVVI. KYGEVVI (doxecitine and doxribtimine) powder, for oral solution Initial U.S. Approval: 202520251110
7d5ce670-9314-4fd7-8b0a-1447910dcf9edoxecitine 2000 MG / doxribtimine 2000 MG Powder for Oral Solution [Kygevvi]SBD3These highlights do not include all the information needed to use KYGEVVI safely and effectively. See full prescribing information for KYGEVVI. KYGEVVI (doxecitine and doxribtimine) powder, for oral solution Initial U.S. Approval: 202520251110
7d5ce670-9314-4fd7-8b0a-1447910dcf9eKygevvi (doxecitine 2 GM / doxribtimine 2 GM) Powder for Oral SolutionSY3These highlights do not include all the information needed to use KYGEVVI safely and effectively. See full prescribing information for KYGEVVI. KYGEVVI (doxecitine and doxribtimine) powder, for oral solution Initial U.S. Approval: 202520251110